Pfizer
Sabine Gilliam has extensive experience in the pharmaceutical industry, holding key leadership roles at Pfizer since January 2010, including Vice President of International Market Access and Pricing, Country President of Pfizer Germany, and various Vice President positions in Japan focused on oncology, inflammation, immunology, and rare diseases. Prior to Pfizer, Sabine held the role of Global Strategic Pricing and Market Access Director at Novartis for a brief period in 2009. Sabine's earlier career includes significant positions at Schering-Plough Pharmaceuticals from 1998 to 2009, including Director of Marketing Operations and Division Director for Specialties in Germany, as well as roles at Grünenthal Group from 1989 to 1997. Sabine holds an MBA from Thunderbird School of Global Management and earned a PhD and MA in English and History from Ruhr University Bochum, with additional study at Trinity College Dublin.
This person is not in any teams
Pfizer
605 followers
Pfizer Inc. is a research-based, global biopharmaceutical company. They apply science and their global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. They work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Pfizer collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Pfizer was founded in 1942. Most of Pfizer’s revenues come from the manufacture and sale of biopharmaceutical products. They believe that their medicines and vaccines provide significant value for healthcare providers and patients, through improved treatment of diseases, improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room or hospitalization. Pfizer is committed to fulfilling their purpose: Breakthroughs that change patients’ lives. Their purpose fuels everything they do and reflects both their passion for science and commitment to patients. Pfizer’s growth strategy is driven by five “Bold Moves” that help them deliver breakthroughs for patients and create value for shareholders and other stakeholders: 1. Unleash the power of our people; 2. Deliver first-in-class science; 3. Transform our go-to-market model; 4. Win the digital race in pharma; and 5. Lead the conversation.